Gain Therapeutics (GANX) Total Non-Current Liabilities (2020 - 2026)

Gain Therapeutics has reported Total Non-Current Liabilities for 7 years, with the latest figure at $696043.0 in Q2 2026.

• On a quarterly basis, Total Non-Current Liabilities fell 26.02% year-over-year to $696043.0 in Q2 2026; TTM through Jun 2026 was $696043.0, a 26.02% decrease from a year earlier, with the FY2025 full-year figure at $901831.0, up 3.3% from the prior year.
• Total Non-Current Liabilities was $696043.0 for Q2 2026 at Gain Therapeutics, down from $844913.0 in the prior quarter.
• The five-year high for Total Non-Current Liabilities was $1.6 million in Q2 2023, with the low at $696043.0 in Q2 2026.
• Average Total Non-Current Liabilities over 5 years is $1.0 million, with a median of $935936.5 recorded in 2024.
• The sharpest annual moves came in 2022 and 2024: Total Non-Current Liabilities increased 24.27% in 2022, then slumped 43.76% in 2024.
• Over 5 years, Total Non-Current Liabilities stood at $1.1 million in 2022, then fell by 1.23% to $1.1 million in 2023, then declined by 19.25% to $872989.0 in 2024, then grew by 3.3% to $901831.0 in 2025, then declined by 22.82% to $696043.0 in 2026.
• The last three Total Non-Current Liabilities figures came in at $696043.0 (Q2 2026), $844913.0 (Q1 2026), and $901831.0 (Q4 2025), per Business Quant data.